Please login to the form below
Alzheon
This page shows the latest Alzheon news and features for those working in and with pharma, biotech and healthcare.
Spinraza keeps Biogen buoyant ahead of Alzheimer’s data
Earlier this week another drug in that category, Alzheon’s tramiprosate, also reported some encouraging data in a mid-stage trial, although that involved a subgroup of patients with a genetic
Latest news
-
Alzheon says data backs potential of Alzheimer's candidate
Four years ago, US biotech Alzheon took a gamble on Alzheimer's candidate tramiprosate, thinking it saw potential in the drug despite a failed phase III trial. ... Like dozens of other shelved amyloid-targeting agents, it would have been all-but
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon
Former GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage biopharmaceutical company Alzheon. ... Alzheon's founder, president and chief executive officer Martin Tolar said:
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- Rare diseases: not so rare after all
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
